Design and synthesis of a biotinylated probe of COX-2 inhibitor nimesulide analog JCC76

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 18, 2011, Pages 5324-5327

  Zhong, Bo ^a   Lama, Rati ^a   Smith, Kerri M ^a   Xu, Yan ^a   Su, Bin ^a  

^a CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

Biotin; COX 2; JCC76; Nimesulide; Probe

Indexed keywords

ANTINEOPLASTIC AGENT; BIOTIN; CYCLOOXYGENASE 2 INHIBITOR; JCC 76; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; BIOTINYLATION; BREAST CANCER; CANCER CELL CULTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; IC 50;

ANTINEOPLASTIC AGENTS; BIOSENSING TECHNIQUES; BIOTINYLATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY TECHNIQUES, SYNTHETIC; CYCLOHEXANECARBOXYLIC ACIDS; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MOLECULAR STRUCTURE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 80051937609     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.07.025     Document Type: Article

References (22)

1. G.P. Boland, I.S. Butt, R. Prasad, W.F. Knox, and N.J. Bundred Br. J. Cancer 90 2004 423
2. N.J. Bundred, and N.L. Barnes Br. J. Cancer 93 Suppl 1 2005 S10
3. H. Clevers N. Engl. J. Med. 354 2006 761
4. C.T. Dang, C.L. Shapiro, and C.A. Hudis Oncology (Williston Park) 16 2002 30
5. D. Mazhar, R. Gillmore, and J. Waxman QJM 98 2005 711
6. A. Agrawal, and I.S. Fentiman Int. J. Clin. Pract. 62 2008 444
7. R.E. Harris, J. Beebe-Donk, and G.A. Alshafie BMC Cancer 6 2006 27
8. L.R. Howe, and A.J. Dannenberg J. Mammary Gland Biol. Neoplasia 8 2003 31
9. T. Iwama J. Gastroenterol. 44 Suppl 19 2009 72
10. B. Rigas, and K. Kashfi J. Pharmacol. Exp. Ther. 314 2005 1
11. F.H. Sarkar, S. Adsule, Y. Li, and S. Padhye Mini Rev. Med. Chem. 7 2007 599
12. X. Song, H.P. Lin, A.J. Johnson, P.H. Tseng, Y.T. Yang, S.K. Kulp, and C.S. Chen J. Natl. Cancer Inst. 94 2002 585
13. J. Zhu, J.W. Huang, P.H. Tseng, Y.T. Yang, J. Fowble, C.W. Shiau, Y.J. Shaw, S.K. Kulp, and C.S. Chen Cancer Res. 64 2004 4309
14. T. Kawamori, S. Nakatsugi, T. Ohta, T. Sugimura, and K. Wakabayashi Adv. Exp. Med. Biol. 507 2002 371
15. S. Nakatsugi, T. Ohta, T. Kawamori, M. Mutoh, T. Tanigawa, K. Watanabe, S. Sugie, T. Sugimura, and K. Wakabayashi Jpn. J. Cancer Res. 91 2000 886
16. M.S. Shaik, A. Chatterjee, and M. Singh Clin. Cancer Res. 10 2004 1521
17. G. Tian, J.P. Yu, H.S. Luo, B.P. Yu, H. Yue, J.Y. Li, and Q. Mei World J. Gastroenterol. 8 2002 483
18. B. Su, M.V. Darby, and R.W. Brueggemeier J. Comb. Chem. 10 2008 475
19. B. Zhong, X. Cai, X. Yi, A. Zhou, S. Chen, and B. Su J. Steroid Biochem. Mol. Biol. 126 2011 10
20. B. Chen, B. Su, and S. Chen Biochem. Pharmacol. 77 2009 1787
21. + 756.3828, found 756.3847.
22. 2 incubator at 37 °C for 2 h. Supernatants were removed from the wells, and the reduced 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide dye was solubilized in 200 μl/well DMSO. Absorbance at 570 nm was determined on a plate reader.